Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 76
Filter
2.
Genome Biol ; 24(1): 187, 2023 08 15.
Article in English | MEDLINE | ID: mdl-37582787

ABSTRACT

BACKGROUND: The international Dog10K project aims to sequence and analyze several thousand canine genomes. Incorporating 20 × data from 1987 individuals, including 1611 dogs (321 breeds), 309 village dogs, 63 wolves, and four coyotes, we identify genomic variation across the canid family, setting the stage for detailed studies of domestication, behavior, morphology, disease susceptibility, and genome architecture and function. RESULTS: We report the analysis of > 48 M single-nucleotide, indel, and structural variants spanning the autosomes, X chromosome, and mitochondria. We discover more than 75% of variation for 239 sampled breeds. Allele sharing analysis indicates that 94.9% of breeds form monophyletic clusters and 25 major clades. German Shepherd Dogs and related breeds show the highest allele sharing with independent breeds from multiple clades. On average, each breed dog differs from the UU_Cfam_GSD_1.0 reference at 26,960 deletions and 14,034 insertions greater than 50 bp, with wolves having 14% more variants. Discovered variants include retrogene insertions from 926 parent genes. To aid functional prioritization, single-nucleotide variants were annotated with SnpEff and Zoonomia phyloP constraint scores. Constrained positions were negatively correlated with allele frequency. Finally, the utility of the Dog10K data as an imputation reference panel is assessed, generating high-confidence calls across varied genotyping platform densities including for breeds not included in the Dog10K collection. CONCLUSIONS: We have developed a dense dataset of 1987 sequenced canids that reveals patterns of allele sharing, identifies likely functional variants, informs breed structure, and enables accurate imputation. Dog10K data are publicly available.


Subject(s)
Wolves , Dogs , Animals , Wolves/genetics , Chromosome Mapping , Alleles , Polymorphism, Single Nucleotide , Nucleotides , Demography
3.
Genes (Basel) ; 14(3)2023 03 04.
Article in English | MEDLINE | ID: mdl-36980922

ABSTRACT

Bernese mountain dogs are a large dog breed formed in the early 1900s in Switzerland. While originally farm dogs that were used for pulling carts, guarding, and driving cattle, today they are considered multi-purpose companion and family dogs. The breed is predisposed to several complex diseases, such as histiocytic sarcoma, degenerative myelopathy, or hip dysplasia. Using whole-genome sequencing (WGS) data, we assessed the genomic architecture of 33 unrelated dogs from four countries: France, Sweden, Switzerland, and the United States. Analysis of runs of homozygosity (ROH) identified 12,643 ROH with an average length of 2.29 Mb and an average inbreeding coefficient of 0.395. Multidimensional scaling analysis of the genetic relatedness revealed limited clustering of European versus USA dogs, suggesting exchanges of breeding stock between continents. Furthermore, only two mtDNA haplotypes were detected in the 33 studied dogs, both of which are widespread throughout multiple dog breeds. WGS-based ROH analyses revealed several fixed or nearly fixed regions harboring discreet morphological trait-associated as well as disease-associated genetic variants. Several genes involved in the regulation of immune cells were found in the ROH shared by all dogs, which is notable in the context of the breed's strong predisposition to hematopoietic cancers. High levels of inbreeding and relatedness, strongly exaggerated in the last 30 years, have likely led to the high prevalence of specific genetic disorders in this breed.


Subject(s)
Genome , Polymorphism, Single Nucleotide , Dogs , Animals , Cattle , Homozygote , Genome/genetics , Genotype , Genomics/methods
4.
Cancers (Basel) ; 14(2)2022 Jan 06.
Article in English | MEDLINE | ID: mdl-35053440

ABSTRACT

Mucosal melanoma (MM) is a rare, aggressive clinical cancer. Despite recent advances in genetics and treatment, the prognosis of MM remains poor. Canine MM offers a relevant spontaneous and immunocompetent model to decipher the genetic bases and explore treatments for MM. We performed an integrative genomic and transcriptomic analysis of 32 canine MM samples, which identified two molecular subgroups with a different microenvironment and structural variant (SV) content. The overexpression of genes related to the microenvironment and T-cell response was associated with tumors harboring a lower content of SVs, whereas the overexpression of pigmentation-related pathways and oncogenes, such as TERT, was associated with a high SV burden. Using whole-genome sequencing, we showed that focal amplifications characterized complex chromosomal rearrangements targeting oncogenes, such as MDM2 or CDK4, and a recurrently amplified region on canine chromosome 30. We also demonstrated that the genes TRPM7, GABPB1, and SPPL2A, located in this CFA30 region, play a role in cell proliferation, and thus, may be considered as new candidate oncogenes for human MM. Our findings suggest the existence of two MM molecular subgroups that may benefit from dedicated therapies, such as immune checkpoint inhibitors or targeted therapies, for both human and veterinary medicine.

5.
PLoS Genet ; 17(4): e1009395, 2021 04.
Article in English | MEDLINE | ID: mdl-33793571

ABSTRACT

Histiocytic sarcoma (HS) is a rare but aggressive cancer in both humans and dogs. The spontaneous canine model, which has clinical, epidemiological, and histological similarities with human HS and specific breed predispositions, provides a unique opportunity to unravel the genetic basis of this cancer. In this study, we aimed to identify germline risk factors associated with the development of HS in canine-predisposed breeds. We used a methodology that combined several genome-wide association studies in a multi-breed and multi-cancer approach as well as targeted next-generation sequencing, and imputation We combined several dog breeds (Bernese mountain dogs, Rottweilers, flat-coated retrievers, and golden retrievers), and three hematopoietic cancers (HS, lymphoma, and mast cell tumor). Results showed that we not only refined the previously identified HS risk CDKN2A locus, but also identified new loci on canine chromosomes 2, 5, 14, and 20. Capture and targeted sequencing of specific loci suggested the existence of regulatory variants in non-coding regions and methylation mechanisms linked to risk haplotypes, which lead to strong cancer predisposition in specific dog breeds. We also showed that these canine cancer predisposing loci appeared to be due to the additive effect of several risk haplotypes involved in other hematopoietic cancers such as lymphoma or mast cell tumors as well. This illustrates the pleiotropic nature of these canine cancer loci as observed in human oncology, thereby reinforcing the interest of predisposed dog breeds to study cancer initiation and progression.


Subject(s)
Cyclin-Dependent Kinase Inhibitor p16/genetics , Dog Diseases/genetics , Genetic Predisposition to Disease , Hematologic Neoplasms/genetics , Histiocytic Sarcoma/genetics , Animals , Chromosome Mapping , Dog Diseases/pathology , Dogs , Genome-Wide Association Study , Haplotypes/genetics , Hematologic Neoplasms/pathology , Hematologic Neoplasms/veterinary , High-Throughput Nucleotide Sequencing , Histiocytic Sarcoma/pathology , Humans
6.
Sci Rep ; 11(1): 877, 2021 01 13.
Article in English | MEDLINE | ID: mdl-33441840

ABSTRACT

Circulating tumor DNA (ctDNA) has become an attractive biomarker in human oncology, and its use may be informative in canine cancer. Thus, we used droplet digital PCR or PCR for antigen receptor rearrangement, to explore tumor-specific point mutations, copy number alterations, and chromosomal rearrangements in the plasma of cancer-affected dogs. We detected ctDNA in 21/23 (91.3%) of histiocytic sarcoma (HS), 2/8 (25%) of oral melanoma, and 12/13 (92.3%) of lymphoma cases. The utility of ctDNA in diagnosing HS was explored in 133 dogs, including 49 with HS, and the screening of recurrent PTPN11 mutations in plasma had a specificity of 98.8% and a sensitivity between 42.8 and 77% according to the clinical presentation of HS. Sensitivity was greater in visceral forms and especially related to pulmonary location. Follow-up of four dogs by targeting lymphoma-specific antigen receptor rearrangement in plasma showed that minimal residual disease detection was concordant with clinical evaluation and treatment response. Thus, our study shows that ctDNA is detectable in the plasma of cancer-affected dogs and is a promising biomarker for diagnosis and clinical follow-up. ctDNA detection appears to be useful in comparative oncology research due to growing interest in the study of natural canine tumors and exploration of new therapies.


Subject(s)
Circulating Tumor DNA/blood , Dog Diseases/blood , Dog Diseases/genetics , Histiocytic Sarcoma/veterinary , Melanoma/veterinary , Mouth Neoplasms/veterinary , Animals , Biomarkers, Tumor/blood , Biomarkers, Tumor/genetics , Circulating Tumor DNA/genetics , DNA Copy Number Variations , Dog Diseases/diagnosis , Dogs , Female , Histiocytic Sarcoma/blood , Histiocytic Sarcoma/diagnosis , Histiocytic Sarcoma/genetics , Lymphoma/diagnosis , Lymphoma/genetics , Lymphoma/veterinary , Male , Melanoma/diagnosis , Melanoma/genetics , Mouth Neoplasms/blood , Mouth Neoplasms/diagnosis , Mouth Neoplasms/genetics , Mutation , Protein Tyrosine Phosphatase, Non-Receptor Type 11/analysis , Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics , Sensitivity and Specificity
7.
Int J Cancer ; 147(6): 1657-1665, 2020 09 15.
Article in English | MEDLINE | ID: mdl-32212266

ABSTRACT

In humans, histiocytic sarcoma (HS) is an aggressive cancer involving histiocytes. Its rarity and heterogeneity explain that treatment remains a challenge. Sharing high clinical and histopathological similarities with human HS, the canine HS is conversely frequent in specific breeds and thus constitutes a unique spontaneous model for human HS to decipher the genetic bases and to explore therapeutic options. We identified sequence alterations in the MAPK pathway in at least 63.9% (71/111) of HS cases with mutually exclusive BRAF (0.9%; 1/111), KRAS (7.2%; 8/111) and PTPN11 (56.75%; 63/111) mutations concentrated at hotspots common to human cancers. Recurrent PTPN11 mutations are associated to visceral disseminated HS subtype in dogs, the most aggressive clinical presentation. We then identified PTPN11 mutations in 3/19 (15.7%) human HS patients. Thus, we propose PTPN11 mutations as key events for a specific subset of human and canine HS: the visceral disseminated form. Finally, by testing drugs targeting the MAPK pathway in eight canine HS cell lines, we identified a better anti-proliferation activity of MEK inhibitors than PTPN11 inhibitors in canine HS neoplastic cells. In combination, these results illustrate the relevance of naturally affected dogs in deciphering genetic mechanisms and selecting efficient targeted therapies for such rare and aggressive cancers in humans.


Subject(s)
Dog Diseases/genetics , Histiocytes/pathology , Histiocytic Sarcoma/genetics , Protein Kinase Inhibitors/pharmacology , Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics , Adult , Aged , Aged, 80 and over , Animals , Biopsy , Cell Line, Tumor , Cell Proliferation/drug effects , Child , Child, Preschool , DNA Mutational Analysis , Disease Models, Animal , Dog Diseases/blood , Dog Diseases/pathology , Dogs , Drug Screening Assays, Antitumor/methods , Female , Histiocytic Sarcoma/drug therapy , Histiocytic Sarcoma/pathology , Histiocytic Sarcoma/veterinary , Humans , Infant , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/genetics , Male , Middle Aged , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinases/metabolism , Mutation , Protein Kinase Inhibitors/therapeutic use , Protein Tyrosine Phosphatase, Non-Receptor Type 11/antagonists & inhibitors , Ribonucleases , Tumor Suppressor Proteins , Young Adult
8.
Vet Comp Oncol ; 18(2): 214-223, 2020 Jun.
Article in English | MEDLINE | ID: mdl-31461207

ABSTRACT

Canine oral melanoma is the first malignancy of the oral cavity in dogs and is characterized by a local invasiveness and a high metastatic propensity. A better knowledge of genetic alterations is expected to improve management of this tumour. Copy number alterations are known characteristics of mucosal melanomas both in dogs and humans. The goal of this study was to explore the prognostic value of somatic focal amplifications on chromosomes (Canis Familiaris [CFA]) 10 and 30 in canine oral melanoma. The cohort included 73 dogs with oral melanoma confirmed by histology, removed surgically without adjuvant therapy and with a minimal follow-up of 6 months. Epidemiological, clinical and histological data were collected and quantitative-PCR were performed on formalin-fixed paraffin-embedded (FFPE) samples to identify specific focal amplifications. The 73 dogs included in the study had a median survival time of 220 days. Focal amplifications on CFA 10 and 30 were recurrent (49.3% and 50.7% of cases, respectively) and CFA 30 amplification was significantly associated with the amelanotic phenotype (P = .046) and high mitotic index (MI; P = .0039). CFA 30 amplification was also linked to poor prognosis (P = .0005). Other negative prognostic factors included gingiva location (P = .003), lymphadenomegaly (P = .026), tumour ulceration at diagnosis (P = .003), MI superior to 6 mitoses over 10 fields (P = .001) and amelanotic tumour (P = .029). In multivariate analyses using Cox proportional hazards regression, CFA 30 amplification (Hazard ratio [HR] = 2.08; P = .011), tumour location (HR = 2.20; P = .005) and histological pigmentation (HR = 1.87; P = .036) were significantly associated with shorter survival time. Focal amplification of CFA 30 is linked to an aggressive subset and constitutes a new prognostic factor.


Subject(s)
Chromosome Aberrations/veterinary , Dog Diseases/genetics , Melanoma/veterinary , Mouth Neoplasms/veterinary , Animals , Dogs , Female , Genetic Predisposition to Disease , Male , Melanoma/genetics , Mitotic Index , Mouth Neoplasms/genetics , Prognosis
9.
Genes (Basel) ; 10(7)2019 06 30.
Article in English | MEDLINE | ID: mdl-31262050

ABSTRACT

Despite recent genetic advances and numerous ongoing therapeutic trials, malignant melanoma remains fatal, and prognostic factors as well as more efficient treatments are needed. The development of such research strongly depends on the availability of appropriate models recapitulating all the features of human melanoma. The concept of comparative oncology, with the use of spontaneous canine models has recently acquired a unique value as a translational model. Canine malignant melanomas are naturally occurring cancers presenting striking homologies with human melanomas. As for many other cancers, dogs present surprising breed predispositions and higher frequency of certain subtypes per breed. Oral melanomas, which are much more frequent and highly severe in dogs and cutaneous melanomas with severe digital forms or uveal subtypes are subtypes presenting relevant homologies with their human counterparts, thus constituting close models for these human melanoma subtypes. This review addresses how canine and human melanoma subtypes compare based on their epidemiological, clinical, histological, and genetic characteristics, and how comparative oncology approaches can provide insights into rare and poorly characterized melanoma subtypes in humans that are frequent and breed-specific in dogs. We propose canine malignant melanomas as models for rare non-UV-induced human melanomas, especially mucosal melanomas. Naturally affected dogs offer the opportunity to decipher the genetics at both germline and somatic levels and to explore therapeutic options, with the dog entering preclinical trials as human patients, benefiting both dogs and humans.


Subject(s)
Dog Diseases/genetics , Melanoma/genetics , Animals , Disease Models, Animal , Dog Diseases/epidemiology , Dog Diseases/pathology , Dogs , Humans , Melanoma/epidemiology , Melanoma/pathology , Mouth Neoplasms/epidemiology , Mouth Neoplasms/genetics , Mouth Neoplasms/pathology , Skin Neoplasms/epidemiology , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Uveal Neoplasms/epidemiology , Uveal Neoplasms/genetics , Uveal Neoplasms/pathology
10.
Genes (Basel) ; 10(6)2019 06 23.
Article in English | MEDLINE | ID: mdl-31234577

ABSTRACT

Mucosal melanomas (MM) are rare aggressive cancers in humans, and one of the most common forms of oral cancers in dogs. Similar biological and histological features are shared between MM in both species, making dogs a powerful model for comparative oncology studies of melanomas. Although exome sequencing recently identified recurrent coding mutations in canine MM, little is known about changes in non-coding gene expression, and more particularly, in canine long non-coding RNAs (lncRNAs), which are commonly dysregulated in human cancers. Here, we sampled a large cohort (n = 52) of canine normal/tumor oral MM from three predisposed breeds (poodles, Labrador retrievers, and golden retrievers), and used deep transcriptome sequencing to identify more than 400 differentially expressed (DE) lncRNAs. We further prioritized candidate lncRNAs by comparative genomic analysis to pinpoint 26 dog-human conserved DE lncRNAs, including SOX21-AS, ZEB2-AS, and CASC15 lncRNAs. Using unsupervised co-expression network analysis with coding genes, we inferred the potential functions of the DE lncRNAs, suggesting associations with cancer-related genes, cell cycle, and carbohydrate metabolism Gene Ontology (GO) terms. Finally, we exploited our multi-breed design to identify DE lncRNAs within breeds. This study provides a unique transcriptomic resource for studying oral melanoma in dogs, and highlights lncRNAs that may potentially be diagnostic or therapeutic targets for human and veterinary medicine.


Subject(s)
Dog Diseases/genetics , Melanoma/genetics , Mouth Neoplasms/genetics , RNA, Long Noncoding/genetics , Animals , Breeding , Dog Diseases/pathology , Dogs , Gene Expression Profiling , Genome/genetics , High-Throughput Nucleotide Sequencing , Humans , Melanoma/pathology , Mouth Neoplasms/pathology , Transcriptome/genetics
11.
Genes (Basel) ; 10(5)2019 05 21.
Article in English | MEDLINE | ID: mdl-31117290

ABSTRACT

White coat color in mammals has been selected several times during the domestication process. Numerous dog breeds are fixed for one form of white coat color that involves darkly pigmented skin. The genetic basis of this color, due to the absence of pigment in the hairs, was suggested to correspond to extreme dilution of the phaeomelanin, by both the expression of only phaeomelanin (locus E) and its extreme dilution (locus I). To go further, we performed genome-wide association studies (GWAS) using a multiple breed approach. The first GWAS, using 34 white dogs and 128 non-white dogs, including White Shepherds, Poodles, Cotons de Tulear and Bichons allowed us to identify two significantly associated loci on the locus E and a novel locus on chromosome 20. A second GWAS using 15 other breeds presenting extreme phaeomelanin dilution confirmed the position of locus I on the chromosome 20 (position 55 Mb pcorrected = 6 × 10-13). Using whole-genome sequencing, we identified a missense variant in the first exon of MFSD12, a gene recently identified to be involved in human, mouse and horse pigmentation. We confirmed the role of this variant in phaeomelanin dilution of numerous canine breeds, and the conserved role of MFSD12 in mammalian pigmentation.


Subject(s)
Genome-Wide Association Study , Melanins/genetics , Membrane Proteins/genetics , Skin Pigmentation/genetics , Animals , Dogs , Horses/genetics , Mice , Mutation, Missense
12.
Hum Genet ; 138(5): 455-466, 2019 May.
Article in English | MEDLINE | ID: mdl-30955094

ABSTRACT

In humans, hereditary sensory neuropathies (HSN), also known as hereditary sensory and autonomic neuropathies (HSAN), constitute a clinically and genetically heterogeneous group of disorders characterized by progressive sensory loss, often accompanied by chronic skin ulcerations and nail dystrophic changes. To date, although around 20 genes have already been discovered, they do not explain the genetic causes of all patients. In dogs, similar neuropathies are also diagnosed, several breeds being predisposed to specific forms of the disease. Indeed, the breed specificity of most canine genetic diseases is due to the small numbers of founders and high levels of inbreeding. Recent knowledge and tools developed to study the canine genome efficiently allows deciphering the genetic bases of such diseases. To date, a dozen breeds are recognized to develop specific HSN. For the Border collie and hunting dog breeds, the genes involved have recently been discovered. Other affected breeds thus constitute potential genetic models, with new genes to be found in dogs that can be considered as candidate genes for human HSAN/HSN. Here, we review the different forms of human and canine HSAN/HSN and we present a novel form in Fox terrier cases, highlighting the advantages of the dog model for such rare human diseases.


Subject(s)
Hereditary Sensory and Autonomic Neuropathies/genetics , Hereditary Sensory and Autonomic Neuropathies/veterinary , Animals , Disease Models, Animal , Dogs , Female , Genetic Predisposition to Disease/genetics , Humans , Inbreeding , Male
13.
Hum Genet ; 138(5): 441-453, 2019 May.
Article in English | MEDLINE | ID: mdl-30904946

ABSTRACT

Retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal disorders eventually leading to blindness with different ages of onset, progression and severity. Human RP, first characterized by the progressive degeneration of rod photoreceptor cells, shows high genetic heterogeneity with more than 90 genes identified. However, about one-third of patients have no known genetic causes. Interestingly, dogs are also severely affected by similar diseases, called progressive retinal atrophy (PRA). Indeed, RP and PRA have comparable clinical signs, physiopathology and outcomes, similar diagnosis methods and most often, orthologous genes are involved. The many different dog PRAs often segregate in specific breeds. Indeed, undesired alleles have been selected and amplified through drastic selection and excessive use of inbreeding. Out of the 400 breeds, nearly 100 have an inherited form of PRA, which are natural animal models that can be used to investigate the genetics, disease progression and therapies in dogs for the benefit of both dogs and humans. Recent knowledge on the canine genome and access to new genotyping and sequencing technologies now efficiently allows the identification of mutations involved in canine genetic diseases. To date, PRA genes identified in dog breeds correspond to the same genes in humans and represent relevant RP models, and new genes found in dogs represent good candidate for still unknown human RP. We present here a review of the main advantages of the dog models for human RP with the genes already identified and an X-linked PRA in the Border collie as a model for orphan X-linked RPs in human.


Subject(s)
Dog Diseases/genetics , Retinal Degeneration/genetics , Retinal Degeneration/veterinary , Retinal Rod Photoreceptor Cells/pathology , Retinitis Pigmentosa/genetics , Animals , Disease Models, Animal , Dog Diseases/pathology , Dogs , Female , Genetic Predisposition to Disease/genetics , Humans , Male , Retinal Degeneration/pathology , Retinitis Pigmentosa/pathology
14.
BMC Cancer ; 18(1): 1219, 2018 Dec 04.
Article in English | MEDLINE | ID: mdl-30514258

ABSTRACT

BACKGROUND: Metastatic melanoma is one of the most aggressive forms of cancer in humans. Among its types, mucosal melanomas represent one of the most highly metastatic and aggressive forms, with a very poor prognosis. Because they are rare in Caucasian individuals, unlike cutaneous melanomas, there has been fewer epidemiological, clinical and genetic evaluation of mucosal melanomas. Moreover, the lack of predictive models fully reproducing the pathogenesis and molecular alterations of mucosal melanoma makes its treatment challenging. Interestingly, dogs are frequently affected by melanomas of the oral cavity that are characterized, as their human counterparts, by focal infiltration, recurrence, and metastasis to regional lymph nodes, lungs and other organs. In dogs, some particular breeds are at high risk, suggesting a specific genetic background and strong genetic drivers. Altogether, the striking homologies in clinical presentation, histopathological features, and overall biology between human and canine mucosal melanomas make dogs invaluable natural models with which to investigate tumor development, including tumor ætiology, and develop tailored treatments. METHODS: We developed and characterized two canine oral melanoma cell lines from tumors isolated from dog patients with distinct clinical profiles; with and without lung metastases. The cells were characterized using immunohistochemistry, pharmacology and genetic studies. RESULTS: We have developed and immunohistochemically, genetically, and pharmacologically characterized. Two cell lines (Ocr_OCMM1X & Ocr_OCMM2X) were produced through mouse xenografts originating from two clinically contrasting melanomas of the oral cavity. Their exhaustive characterization showed two distinct biological and genetic profiles that are potentially linked to the stage of malignancy at the time of diagnosis and sample collection of each melanoma case. These cell lines thus constitute relevant tools with which to perform genetic and drug screening analyses for a better understanding of mucosal melanomas in dogs and humans. CONCLUSIONS: The aim of this study was to establish and characterize xenograft-derived canine melanoma cell lines with different morphologies, genetic features and pharmacological sensitivities that constitute good predictive models for comparative oncology. These cell lines are relevant tools to advance the use of canine mucosal melanomas as natural models for the benefit of both veterinary and human medicine.


Subject(s)
Melanoma/diagnostic imaging , Melanoma/genetics , Mouth Neoplasms/diagnostic imaging , Mouth Neoplasms/genetics , Skin Neoplasms/diagnostic imaging , Skin Neoplasms/genetics , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Cell Line, Tumor , Dogs , Dose-Response Relationship, Drug , Female , Humans , Melanoma/drug therapy , Mice , Mice, Nude , Mouth Neoplasms/drug therapy , Skin Neoplasms/drug therapy , Tumor Cells, Cultured , Xenograft Model Antitumor Assays/methods , Melanoma, Cutaneous Malignant
15.
Sci Rep ; 8(1): 13444, 2018 09 07.
Article in English | MEDLINE | ID: mdl-30194329

ABSTRACT

Long non-coding RNAs (lncRNAs) are a family of heterogeneous RNAs that play major roles in multiple biological processes. We recently identified an extended repertoire of more than 10,000 lncRNAs of the domestic dog however, predicting their biological functionality remains challenging. In this study, we have characterised the expression profiles of 10,444 canine lncRNAs in 26 distinct tissue types, representing various anatomical systems. We showed that lncRNA expressions are mainly clustered by tissue type and we highlighted that 44% of canine lncRNAs are expressed in a tissue-specific manner. We further demonstrated that tissue-specificity correlates with specific families of canine transposable elements. In addition, we identified more than 900 conserved dog-human lncRNAs for which we show their overall reproducible expression patterns between dog and human through comparative transcriptomics. Finally, co-expression analyses of lncRNA and neighbouring protein-coding genes identified more than 3,400 canine lncRNAs, suggesting that functional roles of these lncRNAs act as regulatory elements. Altogether, this genomic and transcriptomic integrative study of lncRNAs constitutes a major resource to investigate genotype to phenotype relationships and biomedical research in the dog species.


Subject(s)
Databases, Nucleic Acid , Gene Expression Regulation/physiology , RNA, Long Noncoding/biosynthesis , Transcriptome , Animals , Dogs , Humans , Organ Specificity , RNA, Long Noncoding/genetics
16.
Diagn Microbiol Infect Dis ; 92(2): 95-101, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29885757

ABSTRACT

The commercial SuperPolymyxin medium (ELITechGroup, Puteaux, France), currently licensed in Europe, is aimed to screen for either intrinsic or acquired colistin resistance in Gram negatives. It was tested for screening colistin-resistant Gram-negative rods from bacterial cultures of 145 colistin-resistant and 86 colistin-susceptible Gram-negative rods isolates. It exhibited a sensitivity and specificity of 95.2% (138/145) and 95.3% (82/86), respectively. The sensitivity for the detection of the 25 isolates carrying plasmid-mediated colistin resistance genes (mcr-1, mcr-2, mcr-3, and mcr-4) from bacterial cultures was of 100%. It was also evaluated for the detection of colistin-resistant Gram-negative rods from 57 rectal swab samples (41 clinical rectal swab samples and from 16 spiked rectal swab samples supplemented with colistin-resistant enterobacterial isolates carrying mcr genes). The overall sensitivity and specificity were of 100% (33/33) and 90.3% (56/62), respectively. The detection of isolates carrying plasmid-mediated mcr-like genes from rectal swabs was achieved with a lowest detection limit of 103 to 104 CFU/mL. The SuperPolymyxin medium is adapted for screening and detection of colistin-resistant isolates from bacterial cultures and rectal swab samples, regardless of the level and the mechanism of colistin resistance. It might be useful in the context of prevention of outbreaks due to colistin-resistant isolates and for epidemiological surveillance.


Subject(s)
Anti-Bacterial Agents/pharmacology , Colistin/pharmacology , Culture Media , Drug Resistance, Bacterial , Gram-Negative Bacteria/drug effects , Polymyxins , Enterobacteriaceae/drug effects , Enterobacteriaceae/isolation & purification , Gram-Negative Bacteria/isolation & purification , Humans , Microbial Sensitivity Tests , Plasmids , Reagent Kits, Diagnostic
17.
Cell Transplant ; 27(7): 1096-1110, 2018 07.
Article in English | MEDLINE | ID: mdl-29871519

ABSTRACT

Growing demonstrations of regenerative potential for some stem cells led recently to promising therapeutic proposals for neuromuscular diseases. We have shown that allogeneic MuStem cell transplantation into Golden Retriever muscular dystrophy (GRMD) dogs under continuous immunosuppression (IS) leads to persistent clinical stabilization and muscle repair. However, long-term IS in medical practice is associated with adverse effects raising safety concerns. Here, we investigate whether the IS removal or its restriction to the transplantation period could be considered. Dogs aged 4-5 months old received vascular infusions of allogeneic MuStem cells without IS (GRMDMU/no-IS) or under transient IS (GRMDMU/tr-IS). At 5 months post-infusion, persisting clinical status improvement of the GRMDMU/tr-IS dogs was observed while GRMDMU/no-IS dogs exhibited no benefit. Histologically, only 9-month-old GRMDMU/tr-IS dogs showed an increased muscle regenerative activity. A mixed cell reaction with the host peripheral blood mononucleated cells (PBMCs) and corresponding donor cells revealed undetectable to weak lymphocyte proliferation in GRMDMU/tr-IS dogs compared with a significant proliferation in GRMDMU/no-IS dogs. Importantly, any dog group showed neither cellular nor humoral anti-dystrophin responses. Our results show that transient IS is necessary and sufficient to sustain allogeneic MuStem cell transplantation benefits and prevent host immunity. These findings provide useful critical insight to designing therapeutic strategies.


Subject(s)
Dog Diseases/therapy , Immunosuppression Therapy/methods , Muscular Dystrophy, Animal/therapy , Stem Cell Transplantation/methods , Allogeneic Cells/immunology , Animals , Dogs , Dystrophin/immunology , Male , Muscular Dystrophy, Animal/immunology , Stem Cells/cytology , Stem Cells/immunology , Transplantation, Homologous/methods
18.
PLoS Genet ; 14(3): e1007264, 2018 03.
Article in English | MEDLINE | ID: mdl-29565995

ABSTRACT

Lethal acrodermatitis (LAD) is a genodermatosis with monogenic autosomal recessive inheritance in Bull Terriers and Miniature Bull Terriers. The LAD phenotype is characterized by poor growth, immune deficiency, and skin lesions, especially at the paws. Utilizing a combination of genome wide association study and haplotype analysis, we mapped the LAD locus to a critical interval of ~1.11 Mb on chromosome 14. Whole genome sequencing of an LAD affected dog revealed a splice region variant in the MKLN1 gene that was not present in 191 control genomes (chr14:5,731,405T>G or MKLN1:c.400+3A>C). This variant showed perfect association in a larger combined Bull Terrier/Miniature Bull Terrier cohort of 46 cases and 294 controls. The variant was absent from 462 genetically diverse control dogs of 62 other dog breeds. RT-PCR analysis of skin RNA from an affected and a control dog demonstrated skipping of exon 4 in the MKLN1 transcripts of the LAD affected dog, which leads to a shift in the MKLN1 reading frame. MKLN1 encodes the widely expressed intracellular protein muskelin 1, for which diverse functions in cell adhesion, morphology, spreading, and intracellular transport processes are discussed. While the pathogenesis of LAD remains unclear, our data facilitate genetic testing of Bull Terriers and Miniature Bull Terriers to prevent the unintentional production of LAD affected dogs. This study may provide a starting point to further clarify the elusive physiological role of muskelin 1 in vivo.


Subject(s)
Acrodermatitis/veterinary , Cell Adhesion Molecules/genetics , Dog Diseases/genetics , Genes, Lethal , Intracellular Signaling Peptides and Proteins/genetics , RNA Splicing , Acrodermatitis/genetics , Animals , Chromosome Mapping , Dogs , Exons , Genome-Wide Association Study , Haplotypes , Real-Time Polymerase Chain Reaction
19.
J Antimicrob Chemother ; 73(5): 1272-1278, 2018 05 01.
Article in English | MEDLINE | ID: mdl-29481600

ABSTRACT

Background: The broth microdilution (BMD) method is currently the recommended technique to determine susceptibility to colistin. Objectives: We evaluated the accuracy of three commercialized BMD panels [Sensititre (ThermoFisher Diagnostics), UMIC (Biocentric) and MicroScan (Beckman Coulter)] to determine colistin susceptibility. Methods: A collection of 185 isolates of Gram-negative bacilli (133 colistin resistant and 52 colistin susceptible) was tested. Manual BMD according to EUCAST guidelines was used as the reference method, and EUCAST 2017 breakpoints were used for susceptibility categorization. Results: The UMIC system gave the highest rate of very major errors (11.3%) compared with the Sensititre and MicroScan systems (3% and 0.8%, respectively). A high rate of major errors (26.9%) was found with the MicroScan system due to an overestimation of the MICs for the non-fermenting Gram-negative bacilli, whereas no major errors were found with the Sensititre and UMIC systems. Conclusions: The UMIC system was easy to use, but failed to detect >10% of colistin-resistant isolates. The MicroScan system showed excellent results for enterobacterial isolates, but non-susceptible results for non-fermenters should be confirmed by another method and the range of MICs tested was narrow. The Sensititre system was the most reliable marketed BMD panel with a categorical agreement of 97.8%.


Subject(s)
Anti-Bacterial Agents/pharmacology , Colistin/pharmacology , Gram-Negative Bacteria/drug effects , Microbial Sensitivity Tests/methods , Diagnostic Errors , Sensitivity and Specificity
20.
Sci Rep ; 7(1): 15680, 2017 Nov 15.
Article in English | MEDLINE | ID: mdl-29142306

ABSTRACT

Genome-wide association studies (GWAS) are widely used to identify loci associated with phenotypic traits in the domestic dog that has emerged as a model for Mendelian and complex traits. However, a disadvantage of GWAS is that it always requires subsequent fine-mapping or sequencing to pinpoint causal mutations. Here, we performed whole exome sequencing (WES) and canine high-density (cHD) SNP genotyping of 28 dogs from 3 breeds to compare the SNP and linkage disequilibrium characteristics together with the power and mapping precision of exome-guided GWAS (EG-GWAS) versus cHD-based GWAS. Using simulated phenotypes, we showed that EG-GWAS has a higher power than cHD to detect associations within target regions and less power outside target regions, with power being influenced further by sample size and SNP density. We analyzed two real phenotypes (hair length and furnishing), that are fixed in certain breeds to characterize mapping precision of the known causal mutations. EG-GWAS identified the associated exonic and 3'UTR variants within the FGF5 and RSPO2 genes, respectively, with only a few samples per breed. In conclusion, we demonstrated that EG-GWAS can identify loci associated with Mendelian phenotypes both within and across breeds.


Subject(s)
Breeding , Exome Sequencing , Genome-Wide Association Study/statistics & numerical data , Quantitative Trait Loci/genetics , Animals , Chromosome Mapping , Dogs , Exome/genetics , Genotype , Polymorphism, Single Nucleotide/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...